If you have been wondering whether Exact Sciences is still worth buying after its huge run, you are not alone. This breakdown is designed to help you decide if the current price makes sense. The stock ...

With new features like an onboard high-resolution camera, integrated scanning wheels, and software connectivity, this device is going to be a game-changer for printers, converters, and ink suppliers.

Abbott is acquiring Exact Sciences for $23 billion, the global healthcare leader announced on Thursday. Exact Sciences shareholders will receive $105 per common share, totaling approximately $21 ...

Exact Sciences has the potential to be a big name in cancer testing and screening in the future. It already has multiple tests, and is working on one that can screen for multiple cancers. And there's ...

Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed ...

Exact Sciences' most important product is driving solid revenue growth. It has launched several others that could help boost sales and jolt the stock. The company's long-term prospects look attractive ...

Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. The deal comes just three months after Thrive ...

Exact Sciences’ (NDAQ: EXAS) history is a tale of two halves. Founded in 1995 in Marlborough, Massachusetts, “Exact,” as the company is known, went public in 2001 but struggled to find its footing, ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 20% year on year to $850.7 million. The company’s full-year ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Exact Sciences has moved to acquire Genomic Health, with plans to bring their cancer screening and diagnostic tests up through a combined commercial organization of about 1,000 employees, including ...